Hearing loss in type 1 diabetes mellitus: a need to understand precise pathological mechanisms and develop novel therapeutic approaches

Joana R. N. Lemos,Nathanael Camick,Christopher A. Fraker,Rahul Mittal,Khemraj Hirani,Giacomo Lanzoni
DOI: https://doi.org/10.3389/fauot.2023.1279818
2023-09-29
Abstract:This integrative review and perspective article synthesizes current knowledge about the co-morbidity of Type 1 Diabetes (T1D) and sensorineural hearing loss (SNHL), affecting an estimated 9.2 per 1,000 T1D patients annually. Combining data from clinical, preclinical, and mechanistic studies, the article elucidates the complex pathological mechanisms contributing to SNHL in T1D. It is established that T1D accelerates age-related SNHL and brings about detrimental changes in the auditory system, including damage to outer hair cells (OHCs), inner hair cells (IHCs), the stria vascularis (SV), and the spiral ligament (SL). Furthermore, T1D-associated peripheral neuropathy, microvascular damage, and chronic inflammation in the inner ear contribute to auditory deficits. Although some consistency exists between animal models and human conditions, notable discrepancies warrant the refinement of preclinical models to more accurately mirror human clinical scenarios. This perspective article highlights the need for targeted research to bridge existing knowledge gaps and accelerate the development of early-stage interventions for SNHL in T1D patients. Advancements in this field hold the promise of enhancing clinical prognosis and improving the quality of life of individuals having T1D.
Medicine
What problem does this paper attempt to address?
The paper attempts to address the relationship between Type 1 Diabetes (T1D) and Sensorineural Hearing Loss (SNHL), specifically including the following aspects: 1. **Pathological Mechanisms**: Investigating the specific pathological mechanisms by which Type 1 Diabetes leads to Sensorineural Hearing Loss, including the impact on cochlear structures such as Outer Hair Cells (OHCs), Inner Hair Cells (IHCs), Spiral Ganglion Neurons (SGNs), etc. 2. **Clinical Association**: Studying the incidence of SNHL in patients with Type 1 Diabetes and its relationship with blood glucose control levels. 3. **Model Improvement**: Pointing out the differences between current animal models and human clinical conditions, emphasizing the need to improve animal models to better simulate the clinical conditions of human Type 1 Diabetes. 4. **Therapeutic Strategies**: Proposing the need for further research to develop early intervention measures for SNHL related to Type 1 Diabetes, thereby improving the clinical prognosis and quality of life of patients. By comprehensively analyzing clinical, preclinical, and mechanistic research data, the paper aims to reveal the complex pathological processes by which Type 1 Diabetes leads to SNHL and emphasizes the importance of progress in this field for improving the quality of life of patients.